Platinum unearths vaccine hot stock; AMA Group dented; Big discount for Decmil

Good evening,

There was one company on everyone's lips all of Tuesday.

Nasdaq-listed Moderna sent markets around the world higher after announcing promising results in an early-stage COVID-19 vaccine trial.

Tonight, we take a look at which Aussie fund manager couldn't be happier with the news. The fund in question has backed the US biotech for 18 months and first invested at about $US23 a share. Moderna shares closed on Tuesday at $US80.

Elsewhere, we take a look at what corporate activity has been going on at smash repairer AMA Group and provide an update on two emergency raisings.

Happy reading,
Sarah Thompson, Anthony Macdonald and Tim Boyd
Street Talk Editors